Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02587598 · OUTCOME

Pharmacokinetics: AUCtau of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib

Study of INCB053914 in Subjects With Advanced Malignancies · Source last updated 2021-12-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
nM*h
Interval / dispersion
Standard Deviation
Time frame
Regimen 2 Week 4

Groups in this outcome

Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib

Combination Treatment Group C: INCB053914 80 mg BID + Ruxolitinib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib6

Reported measurements

Source class 1
Values in nM*h · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib30601730Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1730
        value
        3060
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Combination Treatment Group C: INCB053914 80 mg BID + Ruxolitinib
    id
    OG000
    title
    Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib
param Type
MEAN
reporting Status
POSTED
time Frame
Regimen 2 Week 4
title
Pharmacokinetics: AUCtau of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
type
SECONDARY
unit Of Measure
nM*h

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice